Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
In the past three months, 4 analysts have released ratings for Sangamo Therapeutics (NASDAQ:SGMO), with a mix of bullish and indifferent perspectives. The average 12-month price target has increased to $3.75 from $3.00. Key analysts include Patrick Trucchio from HC Wainwright & Co. and Luca Issi from RBC Capital. Sangamo faces challenges in revenue growth, net margin, ROE, and ROA, but maintains a healthy debt-to-equity ratio.
May 15, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sangamo Therapeutics has received mixed analyst ratings over the past three months, with an increased average price target of $3.75. The company faces significant challenges in revenue growth, net margin, ROE, and ROA, but maintains a healthy debt-to-equity ratio.
The mixed analyst ratings and increased price target suggest a neutral short-term impact. While the company faces significant financial challenges, the healthy debt-to-equity ratio provides some stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100